Overview of Alzheimer s Disease
Today s Objectives Provide an overview of Alzheimer s disease and related dementias Where can individuals, families and professionals get help Services available
What is Dementia? Not a disease, dementia is an umbrella term to describe a group of symptoms, including: Loss of intellectual functions Loss of memory Confusion Behavioral changes Personality changes
Overview of Alzheimer s Disease
Alzheimer s Disease Early-Young Onset Normal Onset Lewy Body Dementia Vascular Dementia (multiinfarct) Fronto- Temporal Lobe Dementias Other Dementias or Delirium Genetic syndromes ETOH related Drugs/toxin exposure Thyroid Depression or other mental conditions Infections- Parkinson s
Alzheimer s Disease A progressive, degenerative disease that attacks certain nerve cells within the brain Ø Damage to cells done years before symptoms appear Ø Sticky plaques on nerve cells prevent neuron firing (information transfer) Ø Cell loss/chemical imbalance leads to decline of brain s abilities Ø No concrete cause has been determined, but age/ genetics are thought to be risk factors Ø Diagnosis made through elimination of other conditions/ diseases
Important Elements of Thought Reasoning Judgment Attention Memory Cognitive Functions (Also called our thinking abilities, brain power, mind, etc.) Language Perception Organization Abstraction From The Savvy Caregiver by Dr. Hepburn
Stages of Alzheimer s Disease Early Stage Memory loss causes small problems Cognitive loss impairs thinking Personality changes Middle Stage Memory loss increases short & long term Cognitive loss Increases Personality Changes become a problem Late Stage Memory loss becomes severe Cognitive losses become severe Personality changes Start of physical changes Final Stage Memory loss is complete Cognition absent Personality absent Physical changes severe
Medications and AD Aricept or Exelon FDA approved for mild, moderate and severe stages Prevents the breakdown of acetylcholine which plays a significant role in memory (higher levels of acetylcholine equals better brain communication) Aricept available in tablet; Exelon in capsule, liquid or patch Postpones the worsening symptoms for some from six to twelve months Namenda FDA approved for moderate to severe stages Regulates the activity of glutamate in the brain (Glutamate plays a key role in memory and learning, however excess glutamate can result in disruption of nerve cell communication or nerve death) Available in tablet and liquid form Slows rate of decline in thinking and the ability to perform ADL s
Causes of Problem Behavior Difficulty with tasks Unfamiliar Surroundings Loud noises, frantic environment Inability to communicate May create behavior problems Physical discomfort
Current AD Facts 5.4 million people in the U.S. have diagnosed AD 1 in 8 people 65 and over develop AD; 85+ is 1 in 2 6,000 Alaskans have Alzheimer s OR a related dementia We estimate by 2020 over 11,000 Alaskans affected In 2010, 54,000 Alaskans were over the age of 65 2020 projected is over 96,000 individuals over the age of 65 Fastest growing senior population in the nation 4 times the national average
Need for services and support Diagnosis of ADRD can be overwhelming; families often feel lost Education and peer support create sense of knowledge is power Help = Strength
Services Available Ø Care Coordination Ø Recreational Ø In-Home Supports Equipment Emergency devices Ø Transportation Ø Education and Support Programs Ø Assisted Living Dementia units Ø Nursing Home Dementia Units Family Caregivers Provide: 35 Million hours Economic Value: 420 Billion
Alzheimer s Resource of Alaska Programs for individuals with memory loss or ADRD Programs for family caregivers Programs for professionals Programs for the General Public
How to Contact Us In person 565 University Ave., St#2 Fairbanks, AK 99709 9:00am 5:00pm Monday-Friday By telephone 907-452-2277 toll free in AK 1-800-478-1080 E-mail jadams@alzalaska.org On the web www.alzalaska.org Offices also located in Palmer, Juneau, Anchorage